Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
Year: 2018
Type: article
Authors: Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan Swords, Robert H. Collins, Gabriel N. Mannis, Daniel A. Pollyea, Will Donnellan, Amir T. Fathi, Arnaud Pigneux, Harry P. Erba, Gabrielle T. Prince, Anthony S. Stein, Geoffrey L. Uy, James M. Foran, Elie Traer, Robert K. Stuart, Martha L. Arellano, James L. Slack, Mikkael A. Sekeres, Christophe Willekens, Sung Choe, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Hua Yang, David Dai, Bin Fan, Meredith Goldwasser, Hua Liu, Sam Agresta, Bin Wu, Eyal C. Attar, Martin S. Tallman, Richard M. Stone, Hagop M. Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Weill Cornell Medicine, Northwestern University, The Ohio State University Wexner Medical Center, Sylvester Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Colorado Anschutz, Sarah Cannon, Massachusetts General Hospital, Centre Hospitalier Universitaire de Bordeaux, University of Alabama at Birmingham, Johns Hopkins University, City Of Hope National Medical Center, Washington University in St. Louis, Mayo Clinic in Florida, Oregon Health & Science University, OHSU Knight Cancer Institute, Medical University of South Carolina, MUSC Hollings Cancer Center, Emory University, Winship Cancer Institute, Mayo Clinic Hospital, Cleveland Clinic, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889545515